Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07240454

Safety and Efficacy of Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma: A Randomized Clinical Trial

Led by Tao Liu · Updated on 2025-11-21

143

Participants Needed

2

Research Sites

52 weeks

Total Duration

On this page

Sponsors

T

Tao Liu

Lead Sponsor

T

Tianjin Medical University General Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

This trial investigates the safety and effectiveness of continuing versus stopping aspirin in patients undergoing conservative treatment for chronic subdural hematoma (cSDH), a condition common in older adults often caused by minor head injuries. The study aims to resolve uncertainties about aspirin management in this group, as continuing aspirin may increase bleeding risk while stopping it might cause blood clots. This randomized clinical trial addresses an important gap, as current guidelines lack consensus on aspirin use during conservative care for cSDH. Participants receive standard conservative treatment for cSDH and are randomly assigned to either continue taking aspirin at 100 mg daily or to stop aspirin during treatment. Both groups follow the same non-surgical care plan. This trial does not involve surgery but focuses on medical management and monitoring over six months. The study compares outcomes between the aspirin continuation and discontinuation groups to inform better treatment decisions. During the study, participants will be closely monitored for changes in their subdural hematoma, neurological status, and any complications. Assessments include brain imaging, functional and cognitive tests, quality of life questionnaires, and tracking of cardiovascular events and adverse effects over six months. Researchers will measure hematoma recurrence or progression as the primary outcome and also evaluate disability levels, need for surgery, mortality, and other health events to understand the impact of aspirin use in conservative cSDH treatment.

CONDITIONS

Brief Title

Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older, male or female
  • Confirmed diagnosis of chronic subdural hematoma by cranial CT and/or MRI
  • Planned for conservative management without surgical evacuation
  • Regular aspirin use at the time of enrollment
  • Signed informed consent by patient or legal representative
Not Eligible

You will not qualify if you...

  • Need for emergency surgery to remove hematoma at enrollment
  • Concurrent use of other anticoagulants or antiplatelet agents that cannot be stopped
  • Chronic subdural hematoma caused by other conditions such as ventriculoperitoneal shunt drainage or brain tumors
  • Active bleeding or major cardiac events within 30 days before enrollment
  • Known bleeding disorders like hemophilia or severe low platelets
  • Unable to provide informed consent or expected difficulty completing follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 6 months

Participants receive conservative treatment for chronic subdural hematoma with randomized aspirin continuation or discontinuation. The treatment involves daily oral aspirin administration at 100 mg for those continuing aspirin, or no aspirin for those discontinuing, alongside standard conservative management.

Regular visits during the 6-month treatment period

Follow-up

Duration - Up to 6 months after treatment start

Participants are monitored for recurrence, progression of hematoma, functional outcomes, and adverse events after the treatment period.

Follow-up visits to assess outcomes at 6 months

Trial Site Locations

Total: 2 locations

1

Xuanwu Hospital Capital Medical University

Beijing, China

Actively Recruiting

2

Tianjin Medical University General Hospital

Tianjin, China

Actively Recruiting

Loading map...

Research Team

T

Tao Liu, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Active 24 Hours Subperiostal vs. Passive Subdural Drainage A...

Chronic Subdural Hematoma

Actively Recruiting

4 locations

Randomized Trial Comparing Adjuvant Tranexamic Acid Versus S...

Chronic Subdural Hematoma

Actively Recruiting

1 location

Chronic Subdural Hematoma Treatment With Embolization Versus...

Chronic Subdural Hematoma

Actively Recruiting

31 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here